GB2184652A - Topical compositions containing nicotinate esters - Google Patents
Topical compositions containing nicotinate esters Download PDFInfo
- Publication number
- GB2184652A GB2184652A GB08622487A GB8622487A GB2184652A GB 2184652 A GB2184652 A GB 2184652A GB 08622487 A GB08622487 A GB 08622487A GB 8622487 A GB8622487 A GB 8622487A GB 2184652 A GB2184652 A GB 2184652A
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- composition according
- nicotinate
- weight
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Abstract
The compositions prevent pressure sores and comprise a slow-acting nicotinate ester, e.g. hexyl nicotinate, in a concentration and formulation insufficient to cause observable erythema but sufficient to promote peripheral blood flow.
Description
1 GB 2 184 652 A 1
SPECIFICATION
Pharmaceutical composition for topical application Thisinvention relatesto pharmaceutical compositions for topical application,and providesanovel 5 composition useful for preventing bed sores.
Patients who are unable for any reason to move themselves frequently suffer from so called "bed sores", more properly pressure sores, which are local areas of ulceration caused by prolonged pressure preventing an adequate blood suppiyto that area.
It is known to use nicotinate esters, e.g. methyl nicotinate, in compositions for topical.appi ication to the 10 skin to produce pronounced local erythema. In such compositions, the nicotinate is normally used in a concentration of, for example, 1 to 2.5%. Such erythema causes a local sensation of warmth which is useful in alleviating certain types of local pain usually of muscular origin. The generation of pronounced and perhaps persistent erythema in an area prone to a pressure sore would, however, be inappropriate since thatwould tend to exacerbate the problem. 15 It has now unexpectedly been discovered that nicotinate esters can be used to improve local blood supply to the skin without causing obvious erythema. This has been demonstrated by the tests described below. The consequence of this discovery is that is is possible to produce a composition which may be used to'increase blood flow in areas affected by pressure sores without inducing local irritation. The local restriction in blood flow caused bythe pressure is thereby alleviated and this substantially prevents the formation of a pressure 20 sore.
The present invention accordingly provides a pharmaceutical composition fortopical application to skin areas prone to pressure sores, comprising a slow-acting nicotinate ester in a concentration sufficientto improve local blood flow (i.e. increased blood cell flux) in an epidermal area without causing obvious erythema, associated with an appropriate vehicle. 25 The nicontinate ester must be "slow-acting", i.e. it should not produce a too rapid and transient effect as it is desirable to reduce the frequency of application of the composition to avoid the inconvenience associated with frequent application. Rapidity of action is related to speed of absorption which depends on molecular size and oil/water solubility. Smaller molecules and those with an oil:water partition coefficient of about 1: 1 are absorbed most efficiently. In orderto slow down the rate of absorption it is necessary to increase the size 30 of the molecule, and this may alterthe solubility characteristics of the molecule in one of two ways, each of which can slow down penetration forthefollowing reasons:
(1) If the molecule becomes more lipid soluble, a depot of the ester is formed in the stratum comeum from which it is only slowly released into the more aqueous environment of the viable epidermis; (2) If the molecule becomes more water soluble, the estertends to remain longer in the formulation and is 35 only slowly released into the stratum corneum.
Methyl nicotinate, for example, is a small molecule with an oil:water partition coefficient of about 1: 1. It therefore acts very rapidly and is unsuitable for use in the present invention. Hexyl nicotinate is an appropriate esterwith more lipid and less water solubility but other suitable nicotinates could also be used. It is a simple matterto test nicotinate esters fortheir potential utility in the present invention. 40 As already mentioned, known nicotinate-containing compositions often contain 1 % or more of a nicotinate ester. This is substantially morethan the proportion required in the present invention. While appropriate concentrations can easily be found by routine experiment using the technique described below, in the case of hexyl nicotinate, an appropriate concentration range is 0.025 to 0.2% by weight of the composition.
Concentrations in the range 0.1 to 0.2% cause erythema in a significant proportion of patients, and it is 45 therefore preferred to use only about 0.025 to 0.075% byweight of hexyl nicotinate based on the weight of the composition.
The composition is preferably made up in the form of a lotion for ease of application. Forthis purposethe vehicle forthe nicotinate ester may be a combination of stearic acid in a proportion of 2 to 8%, for example3 to 8%, by weight of the composition, cetostearyl alcohol in a proportion. of 3 to 6% by weight of composition, 50 and water. These proportions give a lotion, i.e. a composition which can be poured. If a cream is desired, the proportions of stearic acid and cetostearyl alcohol maybe appropriately increased, e.g. up to about 10% by weight in each case.
Preferably, the compositions in accordance with the invention contain other ingredients. Thus, it is desirable to include a zinc supplement, e.g. a zinc soap such as zinc stearate, in the composition to promote 55 healthy skin growth. An appropriate concentration is 0.5 to 2% by weight of the composition.
It is desirable to include a bactericideto protect against microbiological contamination. A cationic bactericide such as cetrimide is included as this has the added advantage that it is an emulsifierwhich promotes the homogeneity and stability of the composition. It may be present in a concentration of 0.5 to 2% W by weight of the composition. Chlorocresol in a concentration of 0.05 to 0.2% by weight maybe for additional 60 preservation.
To provide the treated area of skin with further protection, it maybe advantageous to include in the compositions of the invention an oil soluble polysiloxane such as that sold under the trademark Dimethicone. Such a silicone forms a non-volatile barrier film on the treated area of skin which assists in keeping out infection and reducing local evaporation and thus drying out of the skin. Further, since areas 65 2 GB 2 184 652 A 2 proneto pressure sores arefrequenty areas subjectto friction, it may be advantageousto include a lubricant in the new compositions. Appropriate lubricants are lower alkyl esters of long chain fatty acids ofjor example, 12to 18 carbon atoms, such as isopropyl myristate. The silicone and the lubricant may be presentin a concentration of 5to 10% and 5to 15% byweight of the composition respectively. The upper limit onthe lubricant concentration may be 10% byweight. 5 Other conventional ingredients in compositions for topical application may also be included, e.g. glycerol in a concentration of 0.5to5% byweightof the composition.
The newcompositions may be made bydissolving thewater-soluble ingredients, e.g. the bactericide, in purified water, which has, if necessary, previously been heated to remove dissolved air at a temperatureof preferably 80-1000C.The oily constituents of thevehicle are separately heated, preferablyto 80-1 OWC, andthe 10 oleophilic constituents of the composition arethoroughly mixed in. The aqueous and oily constituentsare then combined and homogenized, preferably at 50-60'C. The nicotinate ester isthen added, preferablyat 40-500C, and finallythe composition isfilled into sterile containers.
The effectof the compositions in accordancewith the invention in promoting local blood flow has been demonstrated using a laser Dopplerflowmeter (see "Laser Doppler Measurementof Cutaneous Blood Flow" 15 G.A. Hollowayand D.M Watkins, Journal of Investigative Dermatology 69,306- 309,(1977)). Thisfiowmeter is usedto shine laser-produced red light into the area of skin understudy before and after treatment. Any increase in the rate of flowof the red blood cells in the illuminated areas produces a difference in the Doppler effectshown bythe reflected light,since reflectionsfrom essentially stationary surfaces can be differentiated bythis meansfrom reflectionsfrorn moving red blood cells. The blood cell flux isthen given bythe productof 20 the numberof red blood celisfound to be moving in the irradiated volume of skin and adjacenttissue andthe mean red blood cell velocity.The results expressed bytheflowmeter indicatethe relative change of the blood cell flux over control conditions, i.e. before application of the composition.
3 GB 2 184 652 A 3 The following table shows the results obtained using the composition of Example 1 below on ten subjects:
SubjectNo. Sex Age Site' Conc.' Erythema' Area 4(CM1) 1 F 30 A v 0 0 5 0.025 0 0 0.05 0.5 80.90 0.10 1 152.26 2 F 38 A v 0 0 10 0.025 0.5 124.05 0.05 1 126.32 0.10 2 119.99 3 M 20 A v 0 0 is 0.025 0 0 0.05 0 32.17 0.10 2 103.06 4 F 37 A v 0 0 20 0.025 0 0 0.05 0 0 0.10 0 0 5 M 51 A v 0 0 25 0.025 0 0 0.05 0,5 89.59 0.10 2 82.80 6 M 40 B v 0 0 30 0.025 0 5.00 0,05 1 91.86 0,10 2 246.74 7 F 19 B v 0 0 35 0.025 0 0 0.05 0.5 22.28 0.10 1 119.97 8 M 35 B v 0 0 40 0,025 0 0 0.05 0 4.29 0.10 0.5 0 9 F 28 B v 0 0 45 0.025 0 0 0.05 0 0 0.10 0.5 5.24 10 F 38 B v 0 0 so 0.025 1 51.59 0.05 1 64.73 0.10 3 199.76 1. A=arms B= buttocks 55 2. % hexyl nicotinate orV=Vehicle only 3. Score 0-3 (0= No erythema, 1 =slight erythema, 2=moderate erythema, 3=severe erythema) 4. Adjusted to a sensitivity of 1, area underthe curve integrates the total change occurring.
4 GB 2 184 652 A 4 SUMMARY
Time to response (mins. S. D.) No. measurable Return 5 Concentration Erythema Area (cm2) responses Initial Peak to zero v 0 0 0 0.025 0.15 18.05 2 5.5 h 0.7 22.5 h 6.4 78.5 t 16.3 10 0.05 0.45 51.21 8 10.6:15.0 27.9 12.3 75.8 19.2 0.10 1.40 102.98 8 7.8 2.3 20.8 6.4 83.3 17.7 is Using an erythema scale of Oto 3, an erythema value of up to 0.5 (which is barely detectable) is considered acceptable. Thefigures for "area" given in the third column are obtained by graphical integration of a graph of blood cell flux againsttime obtained using the laser Dopplerflowmeter. Any figure in this column greater than about 20 may be regarded as indicative of a useful improvement in local blood flow in thetreated area.
Thetable clearly shows that such an improvement can readily be obtained with a degree of erythema of 0.5 or 20 less. Thus the compositions in accordance with the invention make it possible to obtain a useful increase in local blood flowwithout appreciable erythema. The compositions of the present invention are thus useful in preventing pressure sores where is itclesired to stimulate local blood flow without obvious erythema.
An increased local blood flowfollowing application of the composition in accordance with the present invention is observable for typically 10 to 90 minutes after the application. Since continuous improved blood 25 flow is not requred for prevention of pressure sores, application twice orthree times a day is sufficient.
Thefollowing Examples illustrate compositions according to the invention.
Example 1
A composition was formulated containingM by weight): 30 Hexyl Nicotinate 0.05 Zinc Stearate 1.00 StearicAcid 5.00 Cetostearyl Alcohol 4.00 35 Cetrimide 1.00 Dimethicone 350 7.50 lsopropyl Myristate 7.50 Glycerol 2.00 Chlorocresol 0.10 40 PurifiedWater 71.85 100.00 45. This composition 0.05% hexyl nicotinate, the most preferred amount. The other compositions used in the 45 test contained the amounts of hexyl nicotinate specified in the table given above, an appropriate adjustment being made in the amount of water.
Example2
A composition was formulated containing(% by weight): 50 Hexyl Nicotinate 0.05 ZincStearate 1.00 Stearic Acid 3.00 CetostearylAllcohoi 4.00 55 Cetrimide 1.00 Dimethicone350 7.50 lsopropyl Myristate 12.50 Glycerol 2.00 Chlorocresol 0.10 60 Purified Water 68.85 100.00 $5 This composition has the advantage of being less viscous than that of Example 1. 65 GB 2 184 652 A 5 The compositions of Examples land 2 (and other compositions of the invention maybe manufactured as follows:
(a) The purified water is heated preferably to 80-1100'C to remove dissolved air. The cetrimide, g lyceroland chlorocresoi (i.e. the watersoluble ingredients) are added with stirring until completely dissolved.
(b) The aqueous solution obtained is allowed to cool to 50-60'C, preferabiy55'C. 5 (c) The stearic acid, cetostearyl alcohol, dimethicone350, isopropyl myristate and zinc stearate (i.e. the oily vehicle ingredients and the other oleophilic ingredients) are mixed together by warming to 60-100'C, preferably 60'C and a] [owed to cool to 50-60'C, preferably 55'C.
(d) The aqueous phase from step (b) is added to the oily phase from step (c) and the mixture emulsified by homogenisation to produce a smooth lotion. The emulsion is then allowed to cool. 10 (e) The hexyl nicotinate is added to the product step (d) at 40-50'C, preferably 50'C, and mixed in thoroughly.
(f) When the lotion obtained has cooled to 37-43'C, preferably 40'C, it is filled into 350 mi round high density polyethylene bottles or other suitable sterile containers, preferably sealed with a pump dispenser principally constructed of high density polyethylene or other suitable material. is
Claims (12)
1. A pharmaceutical composition fortopical application comprising a slowacting nicotinate ester in a concentration sufficientto cause increased blood cell flux in an epidermal area to which the same 20 composition is applied, but insufficient to cause erythema, and an appropriate vehicle.
2. A composition according to claim 1 in which the nicotinate ester is hexyl nicotinate.
3. A composition according to claim 1 or 2 in which the said nicotinate ester is present in a concentration from 0.025to 0.075% by weight based on the weight of the composition.
4. A composition according to anyone of claims 1 to 3 which also contain a zinc supplement. 25
5. A composition according to claim 4 in which the zinc supplement is a zinc soap.
6. A composition according to claim 4 or 5 in which the zinc supplement is present in a concentration of 0.5to 2% by weight based on the weight of the composition.
7. A composition according to any of claims 1 to 6 in which the vehicle comprises stearic acid, cetostearyl alcohol and water. 30
8. A composition according to claim 7 in which the vehicle comprises 2 to 10% by weight of stearic acid and 2to 10% byweight of cetostearyl alcohol, based on the total weight of the composition, the balance of the composition being water.
9. A composition according to anyone of claims 1 to8 which also contains one or more of a cationic bactericide, an oil soluble polysiloxane, and a lubricant. 35
10. A composition according to claim 9 which contains 0.5to 2% of cetrimide as cationic bactericide, 5to 10% of an oil polysiloxane, and 5 to 15% of isopropyl myristate, the said percentages being by weight based on the total weight of the composition.
11. A composition substantially as hereinbefore described in Example 1 or2.
12. Use of hexyl nicotinate or other slow-acting nicotinate ester in the preparation of a pharmaceutical 40 composition for use in therapy to promote peripheral blood flow without causing observable erythema.
Printed for Her Majesty's Stationery Office by Croydon Printing Company (U K) Ltd,5187, D8991685.
Published by The Patent Office, 25 Southampton Buildings, London WC2A l AY, from which copies maybe obtained.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858523036A GB8523036D0 (en) | 1985-09-18 | 1985-09-18 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8622487D0 GB8622487D0 (en) | 1986-10-22 |
| GB2184652A true GB2184652A (en) | 1987-07-01 |
| GB2184652B GB2184652B (en) | 1989-08-23 |
Family
ID=10585343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB858523036A Pending GB8523036D0 (en) | 1985-09-18 | 1985-09-18 | Pharmaceutical composition |
| GB8622487A Expired GB2184652B (en) | 1985-09-18 | 1986-09-18 | Topical compositions containing hexyl nicotinate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB858523036A Pending GB8523036D0 (en) | 1985-09-18 | 1985-09-18 | Pharmaceutical composition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0220825B1 (en) |
| AT (1) | ATE46083T1 (en) |
| DE (1) | DE3665403D1 (en) |
| ES (1) | ES2000398A6 (en) |
| GB (2) | GB8523036D0 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU87390A1 (en) * | 1988-11-17 | 1990-06-12 | Oreal | USE OF ALPHA-TOCOPHEROL NICOTINATE AND / OR HEXYL NICOTINATE IN A COSMETIC COMPOSITION WITH SLIMMING ACTION |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB620687A (en) * | 1945-05-22 | 1949-03-29 | Winthrop Chem Co Inc | Improvements in or relating to alkyl esters of nicotinic acid |
| GB964444A (en) * | 1960-11-16 | 1964-07-22 | Kabi Ab | Compositions for the treatment of acne |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2431558A (en) * | 1945-05-22 | 1947-11-25 | Winthrop Stearns Inc | Vasodilator compositions comprising alkyl nicotinates |
-
1985
- 1985-09-18 GB GB858523036A patent/GB8523036D0/en active Pending
-
1986
- 1986-09-17 ES ES8601952A patent/ES2000398A6/en not_active Expired
- 1986-09-18 GB GB8622487A patent/GB2184652B/en not_active Expired
- 1986-09-18 DE DE8686307195T patent/DE3665403D1/en not_active Expired
- 1986-09-18 EP EP86307195A patent/EP0220825B1/en not_active Expired
- 1986-09-18 AT AT86307195T patent/ATE46083T1/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB620687A (en) * | 1945-05-22 | 1949-03-29 | Winthrop Chem Co Inc | Improvements in or relating to alkyl esters of nicotinic acid |
| GB964444A (en) * | 1960-11-16 | 1964-07-22 | Kabi Ab | Compositions for the treatment of acne |
Non-Patent Citations (3)
| Title |
|---|
| CHEMICAL ABSTRACTS VOLUME 84 1976, PAGE 353, NO. 155589G (AND PHARM. IND. 1976, 38(2), PAGES 201-207). * |
| THE EXTRA PHARMACOPOEIA MARTINDALE, 28TH EDITION PAGE 1632 (NUMBERS 9240W AND 9243Y)AND PAGE 1620 (NUMBER 9231S) * |
| THE MERCK INDEX 10TH EDITION NUMBERS 6332, 6367 AND 9242 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2184652B (en) | 1989-08-23 |
| EP0220825A2 (en) | 1987-05-06 |
| GB8523036D0 (en) | 1985-10-23 |
| ES2000398A6 (en) | 1988-02-16 |
| EP0220825A3 (en) | 1987-09-09 |
| GB8622487D0 (en) | 1986-10-22 |
| DE3665403D1 (en) | 1989-10-12 |
| EP0220825B1 (en) | 1989-09-06 |
| ATE46083T1 (en) | 1989-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0499399B1 (en) | Analgesic compositions | |
| CN1085523C (en) | Preparation for epidermis and process for its preparation | |
| TWI285552B (en) | O/W-emulsion composition and method of preparation threof | |
| US5013545A (en) | Aqueous gels containing topical medicaments | |
| CA1236021A (en) | Skin treatment composition | |
| NZ200232A (en) | Skin-penetrating pharmaceutical composition in the form of as microemulsion | |
| TW200914056A (en) | Stable high internal phase emulsions and compositions comprising the same | |
| EP0330369A1 (en) | Skin conditioning composition | |
| CA1311194C (en) | Oil-in-water-in-silicone emulsion compositions | |
| WO1998033471A1 (en) | Non-irritating composition for treating acne and other skin conditions | |
| JP4015781B2 (en) | Emulsified composition | |
| US5098717A (en) | Method of treatment for pruritus | |
| KR100722677B1 (en) | Cosmetic composition for high internal phase water-in-oil type emulsion | |
| US5882663A (en) | Topical pain-relieving preparation containing C12 To C18 isoparaffins | |
| US5182104A (en) | Topical virucidal composition for treatment of mucocutaneous tissue | |
| JPH03236320A (en) | Skin drug for external use | |
| US6221403B1 (en) | Topical composition | |
| AU9772498A (en) | Novel formulation for use in pain management | |
| GB2184652A (en) | Topical compositions containing nicotinate esters | |
| JP3515154B2 (en) | Emulsified cosmetic | |
| US6124348A (en) | Vitamin C skin formulations | |
| JP3022541B1 (en) | External preparation | |
| Ricciatti-Sibbald et al. | Dermatologic vehicles | |
| US5447961A (en) | O/W type emulsion containing milk | |
| EP0653938B1 (en) | Topical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19920918 |